Skip to main content
. 2021 Oct 19;3(4):467–487. doi: 10.1016/j.jaccao.2021.09.003

Table 3.

Diagnostic Work-Up in Patients With Suspected AL Amyloidosis

Test/Procedure
Blood/serum testsa CBC with manual differential
Basic metabolic panel
Liver function tests
SPEP+IFE
FLC
LDH
β2 microglobulin
Albumin
High-sensitivity troponin
NT-proBNP
TSH and free T4
Cholesterol panel
PT and PTTb
Urine tests Albumin/creatinine ratio
UPEP+IFE
Imaging studies and diagnostic procedures Bone survey inclusive of long bones and skull and/or PET/CT
ECG
TTE
CMRc
Right heart catheterization (with endomyocardial biopsy if indicated)c
Chest x-ray/CT chestc
Abdominal imagingc
EMGc
GI transitc
Upper and lower endoscopiesc
Pathology specimens Unilateral bone marrow aspirate and biopsy for IHC, Congo red stain, flow cytometry, and CD138-selected cytogenetics and FISH
Biopsy of plasmacytoma, if present
Target organ or fat pad, minor salivary gland or rectum aspirate, for Congo red stain, immunofluorescence and, if available, EM. Typing of amyloid needs to be performed for accurate precursor protein identification.

CBC = cell blood count; EM = electron microscopy; FISH = fluorescent in situ hybridization; FLC = serum free light chain; IFE = immunofixation; IHC = immunohistochemistry; LC-MS = liquid chromatography mass spectrometry; LDH = lactate dehydrogenase; MM = multiple myeloma; PET/CT = positron emission tomography/computed tomography; SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis; other abbreviations as in Table 2.

a

Transthyretin (TTR) gene sequencing should be performed in patients where familial transthyretin amyloidosis is in the differential diagnosis and/or if transthyretin amyloidosis is diagnosed.

b

Factor X absorption onto amyloidosis can lead to PTT prolongation and bleeding diathesis.

c

As needed depending on clinical presentation.